BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

URL Pharma May no Longer be Cash Cow in Philadelphia


3/4/2013 7:44:42 AM

The future looks dicey for the Philadelphia operations of URL Pharma, a decades-old drug company that succeeded in raising the price of a popular gout medicine by 100 times despite an outcry from sufferers of the painful affliction. The price increase was an expected, but unintended, consequence of a Food and Drug Administration program that began in 2006 that tried to lay scientific foundations under medicines in use for decades or centuries, but whose safety and efficacy has not been tested in clinical trials. To get a drug company to pay for such trials, the FDA had to offer something in return, such as market exclusivity. Colchicine, the extract of the autumn crocus plant (also known as meadow saffron), has been used for centuries to deal with the pain of inflamed joints. URL Pharma's subsidiary, Mutual Pharmaceuticals, did enough testing to get approval in 2009 for single-ingredient oral colchicine, which it marketed as Colcrys for the treatment of gout and familial Mediterranean fever. Once the drug was approved, the FDA ordered the nonapproved versions of colchicine removed from the market. URL Pharma took advantage of its new monopoly, raising the price from as little as a nickel per pill to $5 per pill. "This was a case of a well-intentioned FDA and a company that took advantage of a regulatory situation to build a business model that was fantastic," said Audrey Kunis, Temple University Hospital doctor, not entirely approvingly. Dr. Kunis is the president of the American College of Rheumatology, which criticized the decision in 2009. URL Pharma's patented version of colchicine attracted the interest of Takeda Pharmaceuticals Ltd., based in Osaka, Japan, which bought URL Pharma for $800 million in June. But Takeda's only interest was Colcrys, which Takeda said accounted for about 72 percent of the nearly $600 million in sales for URL Pharma in 2011. To reinforce that point, Takeda waited only five months before selling all of URL Pharma -- except for Colcrys -- to India's biggest drug company, Sun Pharmaceuticals Ltd., for an undisclosed price.

Read at Post-Gazette
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES